March 25th, 2020–Xconomy by Sarah de Crescenzo
Regenacy Pharmaceuticals, a biotech formed as part of Celgene’s acquisition of Acetylon Pharmaceuticals in late 2016, has raised $30 million in Series A financing to move its lead program into a Phase 2 proof-of-concept trial this year.
The Waltham, MA-based company is developing treatments to address the underlying cause of peripheral neuropathies—a form of nerve damage in the fingers and toes that causes numbness and tingling—associated with diabetes and other conditions.
Regenacy plans to first evaluate its lead drug candidate, ricolinostat, in diabetic peripheral neuropathy…………
